Tormentic Acid, a major component of suspension cells of eriobotrya japonica, suppresses high-fat diet-induced diabetes and hyperlipidemia by glucose transporter 4 and amp-activated protein kinase phosphorylation

Journal of Agricultural and Food Chemistry

Volumn 62, Issue 44, 2014, Pages 10717-10726

  Wu, Jin Bin ^a   Kuo, Yueh Hsiung ^a   Lin, Cheng Hsiu ^b   Ho, Hui Ya ^c   Shih, Chun Ching ^d  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b FENG YUAN HOSPITAL   (Taiwan)

^c Jen Li Biotech Co Ltd   (Taiwan)

^d NATIONAL YUNLIN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

Author keywords

AMP activated protein kinase phosphorylation; antidiabetes; antihyperlipidemia; glucose transporter 4; tormentic acid

Indexed keywords

AMP-ACTIVATED PROTEIN KINASE; ANTIDIABETES; ANTIHYPERLIPIDEMIA; GLUCOSE TRANSPORTER 4; HIGH-FAT DIET; HYPERLIPIDEMIA; SUSPENSION CELL;

GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORTER 4; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; PLANT EXTRACT; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TORMENTIC ACID; TRIACYLGLYCEROL; TRITERPENE;

ADVERSE EFFECTS; ANIMAL; C57BL MOUSE; CELL CULTURE; CHEMISTRY; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; ENZYMOLOGY; ERIOBOTRYA; GENETICS; GLUCOSE BLOOD LEVEL; GROWTH, DEVELOPMENT AND AGING; HUMAN; HYPERLIPIDEMIAS; LIPID DIET; LIVER; MALE; METABOLISM; MOUSE; PHOSPHORYLATION; SKELETAL MUSCLE;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; BLOOD GLUCOSE; CELLS, CULTURED; DIABETES MELLITUS, TYPE 2; DIET, HIGH-FAT; ERIOBOTRYA; GLUCOSE TRANSPORTER TYPE 4; HUMANS; HYPERLIPIDEMIAS; INSULIN; LIVER; MALE; MICE; MICE, INBRED C57BL; MUSCLE, SKELETAL; PHOSPHORYLATION; PLANT EXTRACTS; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TRIGLYCERIDES; TRITERPENES;

EID: 84908568650     PISSN: 00218561     EISSN: 15205118     Source Type: Journal    
DOI: 10.1021/jf503334d     Document Type: Article

References (49)

1. Stumvoll, M.; Goldstein, B. J.; Van Haeften, T. W. Type 2 diabetes: principles of pathogenesis and therapy Lancet 2005, 365, 1333-1346
2. Basu, A.; Caumo, A.; Bettini, F. Impaired basal glucose effectiveness in NIDDM; contribution of defects in glucose disappearance and production, measured using an optimized minimal model independent protocol Diabetes 1997, 46, 421-432
3. Minokoshi, Y.; Kahn, C. R.; Kahn, B. B. Tissue-specific ablation of the GLUT4 glucose transporter or the insulin receptor challenges assumptions about insulin action and glucose homeostasis J. Biol. Chem. 2003, 278 (36) 33609-33612
4. Joost, H. G.; Bell, G. I.; Best, J. D.; Birnbaum, M. J.; Charron, M. J.; Chen, Y. T.; Dieg, H.; James, D. E.; Lodish, H. J.; Moley, K. H.; Moly, J. F.; Mueckler, M.; Rogers, S.; Schurmann, A.; Seino, S.; Thotens, B. Nomenclature of the GLUT4/SLC2A family of sugar/phylol transport facilitators Am. J. Physiol. Endocrinol. Metab. 2002, 282, 974-976
5. Watson, R. T.; Pessin, J. E. Intracellular organization of insulin signaling and GLUT4 translocation Recent Prog. Horm. Res. 2001, 56, 175-193
6. Sujatha, S.; Anand, S.; Scangeetha, K. N.; Shilpa, K.; Lakshmi, J.; Balakrishnan, A.; Lakshmi, B. S. Biological evaluation of (3β)-stigmast-5-en-3-ol as potent anti-diabetic agent in regulating glucose transport using in vitro model Int. J. Diabetes Mellitus 2010, 2, 101-109
7. Zhou, G.; Myers, R.; Li, Y.; Chen, T.; Shen, X.; Fenyk-Melody, J.; Wu, M.; Ventre, J.; Doebber, T.; Fujii, N.; Musi, N.; Hirshman, M. E.; Goodyear, L. J.; Möller, D. E. Role of AMP-activated protein kinase in mechanism of metformin action J. Clin. Invest. 2001, 108 (8) 1167-1174
8. Foretz, M.; Taleux, N.; Guigas, B.; Horman, S.; Beauloye, C.; Andreelli, F. Regulation of energy metabolism by AMPK: a novel therapeutic approach for the treatment of metabolic and cardiovascular diseases Med. Sci. (Paris) 2006, 22, 381-383
9. Viollet, B.; Lantier, L.; Devin-Leclerc, J.; Hebrard, S.; Amouyal, C.; Mounier, R.; Foretz, M.; Andreelli, F. Targeting the AMPK pathway for the treatment of type 2 diabetes Front. Biosci. (Landmark Ed.) 2009, 14, 3380-3400
10. Musi, N. AMP-activated protein kinase and type 2 diabetes Curr. Med. Chem. 2006, 13 (5) 583-589
11. Noreen, W.; Wadood, A.; Hidayat, H. K.; Wahid, S. A. Effect of Eriobotrya japonica on blood glucose levels of normal and alloxan-diabetic rabbits Planta Med. 1988, 54, 196-199
12. Tommasi, N. D.; Shimone, F. D.; Pizza, C. Constituents of Eriobotrya japonica: a study of their antiviral properties J. Nat. Prod. 1992, 55, 1067-1073
13. Liu, J. Oleanolic acid and ursolic acid: research perspectives J. Ethnopharmacol. 2005, 100, 92-94
14. Ivorra, M. D.; Paya, M.; Villar, A. Hypoglycemic and insulin release effects of tormentic acid: a new hypoglycemic natural product Planta Med. 1988, 54, 282-285
15. Wen, X.; Sun, H.; Liu, J.; Wu, G.; Zhang, L.; Wu, X.; Ni, P. Pentacyclic triterpenes. Part 1: The first examples of naturally occurring pentacyclic triterpenes as a new class of inhibitors of glycogen phosphorylases Bioorg. Med. Chem. Lett. 2005, 15, 4944-4948
16. Taniguchi, S.; Imayoshi, Y.; Kobayashi, E.; Takamatsu, Y.; Ito, H.; Hatano, T.; Sakagami, H.; Tokuda, H.; Nishino, H.; Sugita, D.; Shimura, S.; Yoshida, T. Production of bioactive triterpenes by Eriobotrya japonica calli Phytochemistry 2002, 59, 315-323
17. Shih, C. C.; Lin, C. H.; Wu, J. B. Eriobotrya japonica improves hyperlipidaemia and reverses insulin resistance in high-fat-fed mice Phytother. Res. 2010, 24 (12) 1769-1780
18. Shih, C. C.; Ciou, J. L.; Lin, C. H.; Wu, J. B.; Ho, H. Y. Cell suspension culture of Eriobotrya japonica regulates the diabetic and hyperlipidemic signs of high-fat-fed mice Molecules 2013, 18 (3) 2726-2753
19. Villar, A.; Payá, M.; Hortiguela, M. D.; Cortes, D. Tormentic acid, a new hypoglycemic agent from Poterium ancistroides Planta Med. 1986, 52, 43-45
20. Ivorra, M. D.; Payá, M.; Villar, A. Effect of tormentic acid on insulin secretion in isolated rat islets of Langerhans Phytother. Res. 1989, 3 (4) 145-147
21. Harte, R. A.; Kirk, E. A.; Rosenfeld, M. E.; LeBoeuf, R. C. Initiation of hyperinsulinemia and hyperleptinemia is diet dependent in C57BL/6 mice Horm. Metab. Res. 1999, 31, 570-575
22. Arner, P. Insulin resistance in type 2 diabetes: role of fatty acid Diabetes Metab. Res. Rev. 2002, 18, S5-S9
23. Shen, Q. W.; Jones, C. S.; Kalchayanand, N.; Zhu, M. J.; Du, M. J. Effect of dietary alpha-lipoic acid on growth, body composition, muscle pH, and AMP-activated protein kinase phosphorylation in mice J. Anim. Sci. 2005, 83, 2611-2617
24. Chang, C. T.; Huang, S. S.; Lin, S. S.; Amagaya, S.; Ho, H. Y.; Hou, W. C.; Shie, P. H.; Wu, J. B.; Huang, G. J. Anti-inflammatory activities of tormentic acid from suspension cells of Eriobotrya japonica ex vivo and in vivo Food Chem. 2011, 127, 1131-1137
25. Shih, C. C.; Lin, C. H.; Lin, W. L. Effects of Momordica charantia on insulin resistance and visceral obesity in mice on high-fat diet Diabetes Res. Clin. Pract. 2008, 81 (2) 134-143
26. Shih, C. C.; Lin, C. H.; Lin, Y. J.; Wu, J. B. Validation of the antidiabetic and hypolipidemic effects of hawthorn by assessment of gluconeogenesis and lipogenesis related genes and AMP-activated protein kinase phosphorylation Evidence-Based Complement. Altern. Med. 2013, 2013 597067
27. Shih, C. C.; Shlau, M. T.; Lin, C. H.; Wu, J. B. Momordica charantia ameliorates insulin resistance and dyslipidemia with altered hepatic glucose production and fatty acid synthesis and AMPK phosphorylation in high-fat-fed mice Phytother. Res. 2014, 28 (3) 363-371
28. Klip, A.; Ramlal, T.; Young, D. A.; Holloszy, J. O. Insulin-induced translocation of glucose transporters in rat hindlimb muscles FEBS Lett. 1987, 224 (1) 224-230
29. Shih, C. C.; Lin, C. H.; Lin, W. L.; Wu, J. B. Momordica charantia extract on insulin resistance and the skeletal muscle GLUT4 protein in fructose-fed rats J. Ethnopharmacol. 2009, 123 (1) 82-90
30. Kleiner, D. E.; Brunt, E. M.; Van Natta, M.; Sanyal, A. J. Design and validation of a histological scoring system for nonalcoholic fatty liver disease Hepatology 2005, 41, 1313-1321
31. Petro, A. E.; Cotter, J.; Cooper, D. A.; Peters, J. C.; Surwit, S. J.; Surwit, R. S. Fat, carbohydrate and calories in the development of diabetes and obesity in the C57BL/6J mouse Metabolism 2004, 53, 454-457
32. Martinez, L.; Berenguer, M.; Bruce, M. C.; Le Marchand-Brustel, Y.; Govers, R. Rosiglitazone increases cell surface GLUT4 levels in 3T3-L1 adipocytes through an enhancement of endosomal recycling Biochem. Pharmacol. 2010, 79 (9) 1300-1309
33. Huang, S.; Czech, M. P. The GLUT4 glucose transporter Cell Metab. 2007, 5, 237-252
34. Iglesias, M. A.; Ye, J. M.; Frangioudakis, G.; Saha, A. K.; Tomas, E.; Ruderman, N. B.; Cooney, G. J.; Kraegen, E. W. AICAR administration causes an apparent enhancement of muscle and liver action in insulin-resistant high-fat-fed rats Diabetes 2002, 51, 2886-2894
35. Ye, J. M.; Ruderman, N. B.; Kraegen, E. W. AMP-activated protein kinase and malonyl-CoA: targets for treating insulin resistance? Drug Discovery Today: Ther. Strategies 2005, 2 (2) 157-163
36. Fryer, L. G.; Parbu-Patel, A.; Patel, A. The anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways J. Biol. Chem. 2002, 277, 25226-25232
37. Ahmed, M. H.; Byrne, C. D. Modulation of sterol regulatiry element binding proteins (SREBPs) as potential treatments for non-alcoholic fatty liver disease (NAFLD) Drug Discovery Today 2007, 12 (17-18) 740-747
38. Kurukulasuriya, R.; Link, J. T.; Madar, D. J. Prospects for pharmacologic inhibition of hepatic glucose production Curr. Med. Chem. 2003, 10 (2) 99-121
39. Guignot, L.; Mithieux, G. Mechanisms by which insulin, associated or not with glucose, may inhibit hepatic glucose production in the rat Am. J. Physiol. 1999, 227 (6, Part 1) E984-E989
40. Berg, J. M.; Tymoczko, J. L.; Stryer, L. Glycolysis and glyconeogenesis. In Stryer Biochemistry; Berg, J. M.; Tymoczko, J. L., Eds.; Freeman: New York, 2001; pp 425-464.
41. Kotelevtsev, Y.; Holmes, M. C.; Burchell, A.; Houston, P. M.; Schmoll, D.; Jamieson, P.; Best, R.; Brown, R.; Edwards, C. R.W.; Seckl, J. R.; Mullins, J. J. 11β-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 14924-14929
42. Mackenzie, R. W.; Elliot, B. T. Akt/PKB activation and insulin signaling: a novel insulin signaling pathway in the treatment of type 2 diabetes Diabetes Metab. Syndr. Obes. 2014, 7, 55-64
43. Staels, B.; Dallongeville, J.; Auwerx, K.; Schoonjans, K.; Leitersdorf, E.; Fruchart, J.-C. Mechanism of action of fibrates on lipid and lipoprotein metabolism Circulation 1998, 98, 2088-2093
44. Cases, S.; Stone, S. J.; Zhou, P.; Yen, E.; Tow, B.; Lardizabal, K. D.; Voelker, T.; Farese, R. V., Jr. Cloning of DGAT2, a second mammalian diacylglycerol acyltransferase, and related family members J. Biol. Chem. 2001, 276, 38870-38876
45. Minokoshi, Y.; Kim, Y.-B.; Peroni, O. D.; Fryer, L. G. D.; Muller, C.; Carling, D.; Kahn, B. B. Leptin stimulates fattyacid oxidation by activating AMP-activated protein kinase Nature (London) 2002, 415, 339-343
46. Myers, M. G.; Cowley, M. A.; Münzberg, H. Mechanism of leptin action and leptin resistance Annu. Rev. Physiol. 2008, 70, 537-556
47. Moon, Y. A.; Hammer, R. E.; Horton, J. D. Deletion of ELOVL5 leads to fatty liver through activation of SREBP-1c in mice J. Lipid Res. 2008, 50, 412-423
48. Foretz, M.; Carling, D.; Guichard, C.; Ferre, P.; Foufelle, F. AMP-activated protein kinase inhibits the glucose-activated expression of fatty acid synthase gene in rat hepatocytes J. Biol. Chem. 1998, 273, 14767-14771
49. Bourgeois, F.; Alexiu, A.; Lemonnier, D. Dietary-induced obesity: effect of dietary fats on adipose tissue cellularity in mice Br. J. Nutr. 1983, 49, 17-26